94th European Atherosclerosis Society (EAS) Congress 2026

Latest data from clinical trials of novel triglyceride-lowering agents, presented at the European Atherosclerosis Society Congress 2026 (24-27 May, Athens, Greece) continued to build understanding of how these promising therapeutics can fit into current practice aimed at reducing overall risk of atherosclerotic cardiovascular disease events and acute pancreatitis (AP). Evidence of low triglyceride testing rates […]

Olezarsen reduces the risk of acute pancreatitis (AP) by 85% in patients with TG levels ≥ 880 mg/dL (10 mmol/L), with nine patients needing treatment per year to prevent one case of AP.1 These are the key findings from a pre-specified sub analysis of data from 455 patients with a mean TG level of 1379 […]

Triglyceride testing in patients newly diagnosed with acute pancreatitis (AP) is underutilised, according to a study of electronic health records (EHR) for 32.2 million people in Germany, Italy, Spain and the UK between 2007 and 2025.

Comparable apoC3 and TG reductions are seen in patients treated with plozasiran 25 mg s.c with and without moderate-to-severe renal or moderate hepatic impairment, suggesting there is no need for dose adjustment in these groups.

Data from a large secondary prevention cohort from UK Clinical Practice Research Datalink have confirmed the strong association between elevated TG and increased risk of atherosclerotic cardiovascular disease (ASCVD) events, even when LDL-C is <2.6 mmol/L.

The ANGPTL3 siRNA, AZD1705, has demonstrated a favourable safety profile and dose dependent reductions in ANGPTL3, TG, LDL-C, apoB and non-HDL-C in a Phase 1 single and multiple ascending dose study in patients with mixed dyslipidaemia.